Development
Traws Pharma, Inc.
TRAW
$1.50
-$0.025-1.65%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | -0.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | -0.44% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | -0.44% |
| SG&A Expenses | 6.15% | -2.73% | -10.86% | -10.38% | -6.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.89% | 37.69% | 30.45% | 18.72% | -6.94% |
| Operating Income | -22.17% | -38.22% | -30.87% | -18.98% | 7.01% |
| Income Before Tax | -16.62% | -35.67% | -32.41% | -17.33% | 8.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.62% | -35.67% | -32.41% | -17.33% | 8.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.62% | -35.67% | -32.41% | -17.33% | 8.07% |
| EBIT | -22.17% | -38.22% | -30.87% | -18.98% | 7.01% |
| EBITDA | -22.17% | -38.25% | -30.89% | -19.00% | 7.02% |
| EPS Basic | -16.32% | -26.68% | -14.39% | 8.09% | 37.65% |
| Normalized Basic EPS | -16.34% | -26.68% | -14.38% | 8.11% | 37.65% |
| EPS Diluted | -16.84% | -27.18% | -14.63% | 7.68% | 37.53% |
| Normalized Diluted EPS | -16.34% | -26.68% | -14.38% | 8.11% | 37.65% |
| Average Basic Shares Outstanding | 0.25% | 6.42% | 13.73% | 24.27% | 42.46% |
| Average Diluted Shares Outstanding | 0.25% | 6.42% | 13.73% | 24.27% | 42.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |